Healthcare · Profile from Healthcare Research Companion
IBM Watson Health (now Merative)
IBM's attempt to turn the computer that won Jeopardy! in 2011 into a business that would "outthink cancer". Between 2011 and 2022 IBM built Watson Health through clinical partnerships (WellPoint, Memorial Sloan Kettering, MD Anderson) and more than $4bn of acquisitions (Phytel, Explorys, Merge Healthcare, Truven Health Analytics). It became the best-known cautionary tale in healthcare AI: oncology advice trained on a small number of synthetic cases, a ~$62m MD Anderson project shelved after an audit, reports of "unsafe and incorrect" treatment recommendations, heavy layoffs and a business with ~$1bn of revenue that did not make money. In 2022 IBM sold the data and analytics assets to Francisco Partners for a price reported at ~$1bn, and they became Merative, a private health-data and software company in Ann Arbor, Michigan.
At a glance
- Founded
- Watson question-answering research at IBM Research from ~2006–07; Jeopardy! match broadcast 14–16 February 2011; first healthcare deal with WellPoint (September 2011); IBM Watson Group formed January 2014; IBM Watson Health business unit launched 13 April 2015
- Founders
- Not a start-up. Key figures: David Ferrucci (led the DeepQA/Watson research team); Ginni Rometty (IBM CEO 2012–2020, Watson's main champion); Mike Rhodin (head of the Watson Group from 2014); Deborah DiSanzo (general manager, Watson Health, 2015–2018); John Kelly III (SVP Cognitive Solutions and IBM Research; acting head of Watson Health from October 2018)
- Headquarters
- Watson Health: Cambridge, Massachusetts (from 2015). Merative: Ann Arbor, Michigan (Truven's former base)
- Ownership / structure
- 2011–2022: business unit of IBM (NYSE: IBM). Since 30 June 2022 (company established 1 July 2022): Merative, a standalone company owned by Francisco Partners, with True Wind Capital and Sixth Street as co-investors
- Leadership (2026)
- Merative CEO Gerry McCarthy (since 2022; previously CEO of eSolutions, another Francisco Partners company) per Merative's April 2026 fact sheet. At IBM: Arvind Krishna (CEO since April 2020) ran the sale; Paul Roma was Watson Health general manager at the sale and moved to a senior adviser role at Francisco Partners
- Segment and buyer
- Health IT, data and analytics. Watson Health sold to hospitals and cancer centres (Watson for Oncology, Watson for Genomics, imaging), payers and employers (Truven MarketScan, Health Insights), life-science companies (clinical development, real-world data), and governments (Cúram social programme software, Medicaid analytics)
- Scale
- Watson Health had ~7,000 employees at its 2016–17 peak (reported) and ~$1bn of annual revenue in 2021, not profitable (WSJ, February 2021, reported). Merative (April 2026 fact sheet): more than 12,000 customers, including 4,000+ providers (9 of the top 10 US hospitals), 7,500+ employers, 7 of the 10 largest US health plans, 35+ government agencies and all top 20 pharma companies
- Capital / price
- Acquisitions: Phytel and Explorys (April 2015, prices not disclosed), Merge Healthcare (~$1bn, announced August 2015), Truven Health Analytics (~$2.6bn, announced February 2016); IBM said its health acquisitions totalled more than $4bn. Sale to Francisco Partners announced 21 January 2022; price not disclosed, reported at ~$1bn
- Signature moves (incl. failures)
- Jeopardy! win and WellPoint deal (2011); Memorial Sloan Kettering oncology training and Watson for Oncology (2012–13); MD Anderson Oncology Expert Advisor (work from 2012, announced 2013, on hold late 2016 after ~$62m spent; audit 2017); Watson Group's $1bn bet (2014); Watson Health unit with Phytel and Explorys (2015); Merge Healthcare (2015); Truven (2016); STAT revelations, layoffs and DiSanzo exit (2017–18); Drug Discovery exit and narrowing (2019); sale to Francisco Partners and Merative (2022)
10 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2011
Jeopardy Win and WellPoint Deal
Launch / partnership
2012
Memorial Sloan Kettering Watson for Oncology
Partnership / AI launch
2013
MD Anderson Oncology Expert Advisor
Partnership (failure)
2014
Watson Group Billion Dollar Bet
Restructuring / investment
2015
Merge Healthcare Acquisition
Acquisition
2015
Watson Health Launch Phytel Explorys
Launch / acquisition
2016
Truven Health Analytics Acquisition
Acquisition
2018
STAT Revelations Layoffs and Leadership Exit
Crisis / restructuring
2019
Drug Discovery Exit and Narrowing
Restructuring / product exit
2022
Sale to Francisco Partners and Merative
Divestiture